Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform

Dow Jones

06/09

By Adriano Marchese

Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis.

Shares traded 25% higher ahead of the morning bell at $7.35.

The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases.

The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year.

The company also said the partnership provides a framework to move additional programs into human testing more efficiently.

Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 09, 2026 08:59 ET (12:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2642498856"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642498856\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642498856?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642498856","market":"sh","top_or_hot":-1,"title":"Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n</p>\n<p>\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n</p>\n<p>\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n</p>\n<p>\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n</p>\n<p>\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 08:59 ET (12:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 20:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n</p>\n<p>\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n</p>\n<p>\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n</p>\n<p>\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n</p>\n<p>\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 08:59 ET (12:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAC","symbol_name":"Cartesian Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642498856","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642498856","pubTimestamp":1781009940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis.Shares traded 25% higher ahead of the morning bell at $7.35.The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases.The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year.The company also said the partnership provides a framework to move additional programs into human testing more efficiently.Under the terms of the agreement, WestGene will rec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNAC":"Cartesian Therapeutics","BK4139":"生物科技"},"translate_title":"Cartesian Therapeutics股价因WestGene递送平台许可协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n\n\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n\n\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n\n\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n\n\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n\n\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 08:59 ET (12:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}